PET Imaging of Brain mGluR5 Receptors Using [18F]SP203

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-09-28

Study Completion Date

2015-03-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The metabotropic glutamate subtype five (mGluR5) receptor is a protein found in the brain and is the target for the excitatory chemical messenger glutimate. The purpose of this protocol is to measure mGluR5 receptors in the brain using positron emission tomography (PET) and a research drug called \[18F\]SP203.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PET Imaging of Brain mGluR1 Receptors Using [18F]FIMX

NCT02230592

Anxiety Disorder Major Depressive Disorder

COMPLETED

Imaging of Brain Receptors Using (11C)mGlu1

NCT01420952

Dosimetry Pharmacokinetics

TERMINATED PHASE1

Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1a

NCT01461083

Parkinson Disease

COMPLETED PHASE1

To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding In Brain Using PET (Positron Emission Tomography) In Healthy Volunteers

NCT01173757

Healthy

COMPLETED PHASE1

Imaging mGluR5 and Synaptic Density in Psychiatric Disorders

NCT03898297

Major Depressive Disorder Bipolar Disorder Healthy

ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Metabotropic glutamate receptors are G-protein coupled receptors that respond to glutamate by activating proteins inside nerve cells that affect cell metabolism, thereby fine-tuning the signals sent between cells to maintain balance in neuronal activity. Metabotropic Glutamate receptors (mGluR5) are Group I receptors localized post-synaptically and found in several regions of the brain including the striatum, hippocampus, amygdala, and cortex. Activation of mGluR5 stimulates phospholipase C, resulting in phosphoinositide hydrolysis and increase of intracellular Ca2+ levels. Several potent antagonists for mGluR5 have been developed, including 6 methyl-2-(phenylethynyl)pyridine (MPEP) and 3-\[(2-methyl-1,3-thiazol-4yl)ethynyl\] pyridine (MTEP) however, no simple derivatives of MPEP or MTEP had proven to be useful for in vivo imaging.

In the present protocol, we will use a new PET ligand \[(18)F\]SP203 for two reasons: Part 1.) we will perform kinetic brain imaging to quantify mGluR5 binding parameters in brain and determine the reliability and reproducibility of these measures in 15 healthy controls Part 2.) if the tracer is proved successful in the part 1, we plan to estimate radiation-absorbed doses of \[(18)F\]SP203 in healthy human subjects by performing whole body imaging.

We will also use another new ligand, \[11C\]SP203, which has the same structure as \[(18)F\]SP203 but labeled with (11)C instead of (18)F. Part 3) the same purpose as part 1 but with \[(11)C\]SP203 instead of \[(18)F\]SP203. Part 4) if \[(11)C\]SP203 is proved successful in the part 3, we plan to estimate radiation absorbed doses of \[(11)C\]SP203 in healthy human subjects. At this moment, we do not plan to perform additional scans of \[(18)F\]SP203 under the current protocol. All future subjects will participate in scans of \[(11)C\]SP203.

Additionally, Part 5) we will measure the difference in \[(18)F\]SP203 concentration between the artery and the vein without PET scanning to assess whether the venous blood is a valid and less invasive substitute of arterial blood. In some of \[(18)F\]SP203 scans performed in the current protocol, we compared \[(18)F\]SP203 levels between radial artery and antecubital vein and observed 30% - 60% lower levels in vein. We plan to test whether sampling from a vein in the hand and / or warming up makes \[(18)F\]SP203 levels in vein similar to artery.

Successful development of a PET ligand to image mGluR5 will have a strong impact on clinical management of brain disorders with disruptions in glutamatergic transmission such as schizophrenia, anxiety, and neurodegenerative disorders including Alzheimer s and Parkinson s disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Glutamate Receptor mGlur5 Protein Excitatory Amino Acid Receptors Drug Kinetics PET Scan

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

[18F]SP203

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Healthy control subjects aged 18 65 years, with history/physical exam, ECG, and laboratory tests within one year of the PET scan within normal limits.

Exclusion Criteria

1. Current psychiatric illness, substance abuse or severe systemic disease based on history and physical exam.
2. Laboratory tests with clinically significant abnormalities.
3. Prior participation in other research protocols or clinical care in the last year such that radiation exposure would exceed the annual limits.
4. Pregnancy and breast feeding.
5. Claustrophobia. (part 1 and 3 only)
6. Presence of ferromagnetic metal in the body or heart pacemaker. (part 1 and 3 only)
7. Positive HIV test.
8. Consumed alcohol within 48 hours before the PET scan.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes